Listed as “Kamau Therapeutics”
- First observed:
- 31 Oct 2026
- Investment announced:
- Date not recorded
Company website description: Kamau Therapeutics is a clinical-stage gene correction company focused on developing curative, single-dose precision therapies for serious genetic diseases using high-efficiency targeted DNA integration.
Some source history is available; coverage remains limited.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Listed as “Kamau Therapeutics”
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.